High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma

High‐dose methotrexate (HDMTX) is used frequently in combination regimens that include nephrotoxic chemotherapy. The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome.

[1]  C. Poquette,et al.  Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. , 2000, Journal of pediatric hematology/oncology.

[2]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[3]  S. Bielack,et al.  Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Ferrari,et al.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Souhami,et al.  Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup , 1997, The Lancet.

[6]  M. Wharam,et al.  Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. , 1994, The American journal of pediatric hematology/oncology.

[7]  M. Relling,et al.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  U. Bode,et al.  Methotrexate pharmacokinetics and prognosis in osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Craft,et al.  A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Rosen,et al.  Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience , 1992, Cancer.

[11]  S. Bielack,et al.  Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. , 1991, Clinical orthopaedics and related research.

[12]  J. Shuster,et al.  Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. , 1991, Clinical orthopaedics and related research.

[13]  G. Vawter,et al.  Osteosarcoma in young children , 1991, Cancer.

[14]  N. Jaffe,et al.  Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Browman,et al.  Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Usui,et al.  [Adjuvant chemotherapy of osteosarcoma]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[17]  M. van Glabbeke,et al.  Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation , 1988, Cancer.

[18]  N. Jaffe,et al.  Renal toxicity with cumulative doses of cis‐diamminedichloroplatinum‐II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion , 1987, Cancer.

[19]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[20]  W. Ebell,et al.  Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. Evans,et al.  The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[23]  G. Rosen,et al.  Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. , 1979, Cancer.

[24]  M. Romsdahl,et al.  Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. , 1979, Cancer treatment reports.

[25]  F. Sirotnak,et al.  Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. , 1978, Cancer research.

[26]  S. Rosenberg,et al.  Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. , 1977, The New England journal of medicine.

[27]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[28]  G. Schwartz,et al.  A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine , 2004 .

[29]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[30]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  C. Pratt,et al.  Pharmacokinetic monitoring of high-dose methotrexate , 2004, Cancer Chemotherapy and Pharmacology.

[33]  E. Pignotti,et al.  Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. , 2002, The Journal of bone and joint surgery. British volume.

[34]  A. Pappo,et al.  Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Ferrari,et al.  Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. , 1998, Acta oncologica.

[36]  A. Huvos,et al.  Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Link.  The multi-institutional osteosarcoma study: an update. , 1993, Cancer treatment and research.

[38]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Jasmin,et al.  Importance of age and methotrexate dosage: prognosis in children and young adults with high-grade osteosarcomas. , 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[40]  Age and dose of chemotherapy as major prognostic factors in a trial of adjuvant therapy of osteosarcoma combining two alternating drug combinations and early prophylactic lung irradiation , 1988, Cancer.

[41]  J F Boisvieux,et al.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.

[42]  F. Chu.  The Memorial Hospital Experience , 1980 .

[43]  C. Townsend,et al.  High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. , 1976, Medical and pediatric oncology.

[44]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[45]  F. Ruddle,et al.  Report of the committee on the genetic constitution of autosomes other than chromosomes 1,2 and 6. , 1976, Birth defects original article series.

[46]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .